Screener
Vaxcyte, Inc. PCVX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (345,850) | (180,793) |
| Other income, net: | ||
| Interest income | 26,610 | 32,935 |
| Other income (expense) | (1,382) | 7,140 |
| Total other income, net | 25,228 | 40,075 |
| Net loss | $(320,622) | $(140,718) |
| Net loss per share, basic and diluted | $(2.30) | $(1.04) |
| Weighted-average shares outstanding, basic and diluted | 139,506,680 | 135,690,949 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s EPS (diluted)?
- Vaxcyte, Inc. (PCVX) reported EPS (diluted) of -$2.30 in Q1 2026.
- How has Vaxcyte, Inc.'s EPS (diluted) changed year-over-year?
- Vaxcyte, Inc.'s EPS (diluted) decreased by 121.2% year-over-year, from -$1.04 to -$2.30.
- What is the long-term trend for Vaxcyte, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s EPS (diluted) has grown at a 30.8% compound annual growth rate (CAGR), from -$1.92 to -$5.62.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Vaxcyte, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude